Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Apellis Pharmaceuticals Inc
(NQ:
APLS
)
35.63
+0.10 (+0.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
826,630
Open
35.79
Bid (Size)
35.50 (2)
Ask (Size)
35.99 (5)
Prev. Close
35.53
Today's Range
35.49 - 37.06
52wk Range
33.49 - 73.80
Shares Outstanding
116,457,008
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Analyst Scoreboard: 15 Ratings For Apellis Pharmaceuticals
September 13, 2024
Via
Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Performance
YTD
-41.85%
-41.85%
1 Month
-7.62%
-7.62%
3 Month
-10.32%
-10.32%
6 Month
-35.82%
-35.82%
1 Year
-26.23%
-26.23%
More News
Read More
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
August 29, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Wedbush Just Raised its Price Target on These 7 Stocks: August 12, 2024
August 13, 2024
Via
InvestorPlace
Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know
August 02, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Apellis Pharmaceuticals Through Analyst Insights
July 17, 2024
Via
Benzinga
What Analysts Are Saying About Apellis Pharmaceuticals Stock
June 28, 2024
Via
Benzinga
Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
August 08, 2024
Via
Benzinga
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
August 08, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 06, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts
May 28, 2024
Via
Benzinga
In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals
May 08, 2024
Via
Benzinga
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
August 01, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
July 18, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
July 09, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
June 28, 2024
Via
Benzinga
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
June 28, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
June 10, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
May 24, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
May 14, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
APLS Stock Earnings: Apellis Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024
May 07, 2024
Via
InvestorPlace
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
May 07, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
May 06, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 01, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.